Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ain Shams University | OTHER |
Not provided
Not provided
Not provided
The aim of the current study is to investigate the association between hormonal intake, occupational and demographic factors, and the risk of breast cancer (BC) among Egyptian females.
Methodology Design. A case-controlled study.
Setting. Breast cancer clinic and breast cancer screening unit at clinical oncology department, Ain Shams University hospital
Participants.
All cases who will be screened from the BC clinic and the BC screening unit will be assessed for eligibility according to the following inclusion & exclusion criteria:
Inclusion criteria
Age > 18 and < 70
Exclusion criteria
Eligible candidates will be stratified as cases or matched controls as follows:
Ethical consideration. The protocol will be approved by the ethical committee of NGU and the Clinical Oncology department ASU. The study will be registered at clinicaltrials.gov
Methods.
Data collection for both groups will be done through reviewing of the participants' medical records retrospectively Data collection will include the following data:
Demographic data: name, age, sex, residence
Anthropometric data: height, weight, waist & hip circumference & waist to hip ratio and BMI calculation
Female & menopausal status, age at menarche
Medical history & comorbidity (CVS, DM 1 or 2, HTN)
Family history of other cancers, diabetes
Occupational history
Social history: smoking, recreational drug use, marital status, nulliparity/multi-parity and lactation
Dietary habits and diet composition
Lifestyle habits and degree of regular activity (sedentary, active, etc.)
History of hormonal use as follows:
Breast cancer classification:
Statistical analysis The frequency distribution of the parameters will be assessed. Parametric data will be presented as mean & standard deviation, while non parametric data will be presented as median & IQR. All data will be analyzed using the appropriate statistical test. Proportions will be presented using number & proportion and will be assessed by the Chi square.
Multiple logistic regression analysis will be used to calculate odds ratios (OR) and corresponding 95% confidence intervals (CI) for the various studied factors in relation to breast cancer occurrence & subtypes.
Moreover, the effect of the combined significant factors to the risk of breast cancer development will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cases | 1.Cases (100) are those eligible patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). |
| |
| Matched Controls | 2. Matched controls (100) are those participants presenting to the screening clinic and were not diagnosed with breast cancer during the past 2 years to 2021 (2019-2020). Candidates are to be of same range of age (+/-3 years); and similar visiting period (+/-2 months). All controls were confirmed as having no diagnosis of breast cancer, with negative findings on physical breast examination, and breast sono-mammographic screening. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dydrogesterone Tablets, Norethisterone acetate, Ethinyl estradiol, Drospirenone and ethinyl estradiol | Drug | History of hormonal use as follows:
|
| Measure | Description | Time Frame |
|---|---|---|
| Confirmed Breast Cancer Patients | Patients who were diagnosed with histopathologically confirmed breast cancer and were during the past 2 years to 2021 (2019-2020). | During the past 2 years to 2021 (2019-2020). |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Eligible candidates will be stratified as cases or matched controls as follows:
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nermeen Ashoush, PhD | Contact | +201001809397 | nermeen.ashoush@ngu.edu.eg |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| ID | Term |
|---|---|
| D000077563 | Norethindrone Acetate |
| D004997 | Ethinyl Estradiol |
| C035144 | drospirenone |
| ID | Term |
|---|---|
| D009640 | Norethindrone |
| D009652 | Norpregnenes |
| D009650 | Norpregnanes |
| D009654 | Norsteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D009651 | Norpregnatrienes |
| D042782 | Estrogenic Steroids, Alkylated |
| D045166 | Estradiol Congeners |
| D012739 | Gonadal Steroid Hormones |
| D042341 | Gonadal Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
Not provided
Not provided